Indication AMZEEQ is a topical form of the antibiotic minocycline for the treatment of pimples and red bumps (non-nodular inflammatory lesions) that happen with moderate to severe acne in adults and children 9 years of age and older. BRIDGEWATER, N.J., Feb 01, 2021 (GLOBE NEWSWIRE via COMTEX) -- BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE… WELCOME TO THE STOCKGURU TEAM!!! Menlo's 1st product AMZEEQ was FDA approved/launched in January 2020 (~$200MM estimated peak sales). It is not taken by mouth. AMZEEQ® label update includes new information indicating the low propensity of Propionibacterium acnes (more commonly known as “P. Further, the prevalence of minocycline-resistant strains as assessed by spontaneous mutation frequency was low (range: <2.7x10-9 to <1.30x10-8 colony forming units) when exposed to minocycline at concentrations up to 16-fold higher than the mean minimum inhibitory concentration (MIC). VYNE may use its website to comply with its disclosure obligations under Regulation FD. The FDA approval was supported by an extensive antimicrobial characterization program by VYNE for both AMZEEQ and minocycline that was published last year in the peer-reviewed journal Anaerobe.1 The program evaluated the on-target potency of AMZEEQ and minocycline against P. acnes and further evaluated the potential for the development of minocycline-resistant strains that could reduce the potency of AMZEEQ in the treatment of acne. AMZEEQ should not be used in people who are allergic to AMZEEQ or any tetracycline medicine. Menlo Therapeutics Announces Corporate Name Change To Vyne Therapeutics. “Both dermatologists and payors have had keen interest in antimicrobial resistance data as they balance patient care with antibiotic stewardship,” said Matt Wiley, Chief Commercial Officer for VYNE. AMZEEQ label update includes new information indicating the low propensity of Propionibacterium acnes (more commonly known as “P. J. Sutcliffe, R. McLaughlin, G. Webster, A. F. Read, K. Drlica, R. Elliot and I. Stuart. Media Relations: Bridgette Potratz Zeno Group 312-358-2950 bridgette.potratz@zenogroup.com, Investor Relations: Joyce Allaire LifeSci Advisors, LLC 646-889-1200 jallaire@lifesciadvisors.com, Andrew Saik Chief Financial Officer VYNE Therapeutics 908-731-6180 Andrew.Saik@vynetx.com, Cautionary Statement Regarding Forward-Looking Statements. BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company People are encouraged to report negative side effects of prescription drugs to the FDA. However, tetracyclines, when taken by mouth (capsules or tablets), may cause serious side effects, including: diarrhea which may be caused by an infection and can cause watery or bloody stools; loss of appetite; tiredness; yellowing of the skin or eyes (jaundice); bleeding more easily than normal; confusion; sleepiness; vision changes, including blurred vision, double vision, or permanent vision loss; unusual headaches; fever; rash; joint pain; body weakness; discoloration or darkening of the skin, scars, teeth, or gums. For a complete copy of the AMZEEQ product label, including the recent update, please see AMZEEQ full Prescribing Information. If approved, FMX103 is targeted to be the first FDA-approved minocycline treatment for rosacea ever. Acne affects approximately 40 to 50 million people in the U.S. alone, of whom approximately 10 million have moderate to severe disease that may impact self-esteem and quality of life. People should not drive or operate dangerous machinery if they have these symptoms. Menlo Therapeutics Q2 Revenue $11.7 Million . VYNE Therapeutics™ is working to solve some of today’s most difficult therapeutic challenges. VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update. AMZEEQ should not be used for the treatment of infections. People are encouraged to report negative side effects of prescription drugs to the FDA. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts. People should call their doctor right away if these side effects occur. You can read further details here. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at amzeeq.com and ZILXI’s Full Prescribing Information at zilxi.com. acnes”) to develop resistance to minocycline. About Acne Acne is a chronic, inflammatory skin condition that affects the skin’s sebaceous glands and hair follicles. AMZEEQ is not for use in the mouth, eyes, or vagina. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at amzeeq.com and ZILXI’s Full Prescribing Information at zilxi.com. The studies concluded that on-target potency remained consistently high (MIC90 = 0.25µg/ml) when tested in clinical isolates of P. acnes. All statements in this press release which are not historical facts are forward-looking statements. People should call their doctor right away if these side effects occur. Amongst other objectives, the antimicrobial characterization program conducted by VYNE to support this label update evaluated on-target potency of AMZEEQ and minocycline against P. acnes and further evaluated the potential for the development of minocycline-resistant strains that could reduce the potency of AMZEEQ in the treatment of acne. VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond. 5 Stocks to make up … ... More articles issued by VYNE Therapeutics … BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval … The AP news staff was not involved in its creation. 1 The program evaluated the on-target potency of AMZEEQ and minocycline against P. acnes and further evaluated the potential for the development of minocycline-resistant strains that could reduce the potency of AMZEEQ in the treatment of acne. The most common side effect of AMZEEQ is headache. VYNE Therapeutics Inc. (VYNE), a specialty pharmaceutical company focused on developing and commercializing proprietary th... VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update. Specifically, the FDA-approved AMZEEQ label now provides that with respect to resistance, P. acnes strains displayed a low propensity for the development of resistance to minocycline, with spontaneous mutation frequencies occurring <10−8 (or 1 in 100 million) at 2 to 16 times the minimum inhibitory concentration (MIC). The FDA approval was supported by an extensive antimicrobial characterization program by VYNE for both AMZEEQ and minocycline that was published last year in the peer-reviewed journal Anaerobe. It is not taken by mouth. The FDA approval was supported by an extensive antimicrobial characterization program by VYNE for both AMZEEQ and … VYNE Therapeutics Announces FDA Approval of AMZEEQ (R) (Minocycline) Label Update. Trending now. AMZEEQ is flammable and fire, flame, and smoking must be avoided when applying and right after applying AMZEEQ. acnes”) to develop resistance to minocyclineBRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on … AMZEEQ® label update includes new information indicating the low propensity of Propionibacterium acnes (more commonly known as “P. AMZEEQ should not be used in women who are pregnant, may become pregnant or are nursing. Use of AMZEEQ should be stopped if skin is sunburned. AMZEEQ is available by prescription only. acnes”) to develop resistance to minocyclineBRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE… VYNE may use its website to comply with its disclosure obligations under Regulation FD. I discuss VYNE Stock today and how this company called Vyne Therapeutics is up +70% in the premarket earlier today 1-25-2021. © 2021 Vyne Therapeutics Inc. All Rights Reserved, VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update, Vyne Therapeutics Inc. All Rights Reserved. About VYNE Therapeutics Inc. VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond. BRIDGEWATER, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of … VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) announced that its Board of Directors has approved a reverse stock split of the Company’s common stock at a ratio of 1-for-4. If a woman becomes pregnant while using AMZEEQ, she should talk to her doctor. #ShortsI have created this channel in order to provide finance related news to more people. The update to the microbiology section in the label further states that although the clinical significance is unknown, the active ingredient in AMZEEQ (minocycline), is proven to be active in vitro against most isolates of P. acnes. BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval by the U.S. Food and Drug Administration ("FDA") to include new … Resistant strains of P. acnes are common although primarily linked to the macrolide and lincosamide class of antibiotic use (erythromycin and clindamycin respectively); there is little evidence of cross-resistance development to the tetracycline class of antibiotics such as minocycline.2, VYNE’s Antimicrobial Characterization Program. The FDA approval was supported by an extensive antimicrobial characterization program by VYNE for both AMZEEQ and minocycline that was published last … With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST)™, and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI® (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST)™, and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI® (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. The reverse stock split was previously approved by stockholders at the Annual Meeting of Stockholders held on August 3, 2020. Connect with the definitive source for global and local news. Media Relations:Bridgette PotratzZeno Group312-358-2950bridgette.potratz@zenogroup.com, Investor Relations:Joyce AllaireLifeSci Advisors, LLC646-889-1200jallaire@lifesciadvisors.com, Andrew SaikChief Financial OfficerVYNE Therapeutics908-731-6180Andrew.Saik@vynetx.com, Cautionary Statement Regarding Forward-Looking Statements. BRIDGEWATER, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its Board of Directors has approved a reverse stock split of the Company's common stock at a ratio of 1-for-4. Seeking Alpha - VYNE Therapeutics (NASDAQ:VYNE) has gained ~38.9% since the company announced last week that the FDA has authorized the inclusion of new information … VYNE Therapeutics surged ~39% since FDA approval for label update (NASDAQ:VYNE) - … VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced approval by the U.S. Food and Drug Administration (“FDA”) to include new information in the product label for AMZEEQ® … “The risk of antimicrobial resistance is a primary concern for dermatologists or, indeed, any routine prescriber of antibiotics,” said David Domzalski, CEO of VYNE. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events. About AcneAcne is a chronic, inflammatory skin condition that affects the skin’s sebaceous glands and hair follicles. VYNE Therapeutics surged ~39% since FDA approval for label update Seeking Alpha 7d Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More AMZEEQ is a topical foam that contains minocycline, a tetracycline medicine. AMZEEQ is not for use in the mouth, eyes, or vagina. ... May 22, 2020 9:10 AM ET VYNE Therapeutics Inc. (VYNE) 30 Comments 7 Likes. The use of antibiotics to counteract the effect of this bacterium remains a major cornerstone of acne disease management, although concerns over the development of antibiotic-resistant strains are factors in a prescriber’s choice of antibiotic and route of administration. F. Schafer, F. Fich, M. Lam C. C Garate, A Wozniak and P Garcia. Visit the post for more. BRIDGEWATER, N.J., Feb. 01, 2021 — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval by the U.S. Food and Drug Administration (“FDA”) to include new information in the product label for … FMX103 is VYNE Therapeutics’s investigational proprietary 1.5% minocycline foam formulation being developed for inflammatory lesions of rosacea in adults. GlobeNewswire Mon, Feb. 01. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events. AMZEEQ is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. ... About VYNE Therapeutics Inc. VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond. DOW 0.38%. The reverse stock split was previously approved by … AMZEEQ is flammable and fire, flame, and smoking must be avoided when applying and right after applying AMZEEQ. “Both dermatologists and payors have had keen interest in antimicrobial resistance data as they balance patient care with antibiotic stewardship,” said Matt Wiley, Chief Commercial Officer for VYNE. VYNE Therapeutics Inc. (VYNE), a specialty pharmaceutical company focused on developing and commercializing proprietary th... VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond. Visit the post for more. BRIDGEWATER, N.J., … However, tetracyclines, when taken by mouth (capsules or tablets), may cause serious side effects, including: diarrhea which may be caused by an infection and can cause watery or bloody stools; loss of appetite; tiredness; yellowing of the skin or eyes (jaundice); bleeding more easily than normal; confusion; sleepiness; vision changes, including blurred vision, double vision, or permanent vision loss; unusual headaches; fever; rash; joint pain; body weakness; discoloration or darkening of the skin, scars, teeth, or gums. vynetherapeutics.com or follow VYNE on Twitter. Recently in News on February 1, 2021, VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update. With every problem we take on, our approach is the same: question traditional assumptions and find a better solution. AMZEEQ® label update includes new information indicating the low propensity of Propionibacterium acnes (more commonly known as “P. vynetherapeutics.com or follow VYNE on Twitter. 10 min read. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. An icon used to represent a menu that can be toggled by interacting with this icon. These risks and uncertainties include, but are not limited to: the COVID-19 pandemic and its impact on our business operations; adverse events associated with the commercialization of AMZEEQ and ZILXI; the outcome and cost of clinical trials for current and future product candidates; determination by the FDA that results from VYNE’s clinical trials are not sufficient to support registration or marketing approval of product candidates; the outcome of pricing, coverage and reimbursement negotiations with third party payors for AMZEEQ, ZILXI or any other products or product candidates that VYNE may commercialize in the future; whether, and to what extent, third party payors impose additional requirements before approving AMZEEQ and ZILXI prescription reimbursement; the eligible patient base and commercial potential of AMZEEQ, ZILXI or any of VYNE’s other products or product candidates; risks that VYNE’s intellectual property rights, such as patents, may fail to provide adequate protection, may be challenged and one or more claims may be revoked or interpreted narrowly or will not be infringed; risks that any of VYNE’s patents may be held to be narrowed, invalid or unenforceable or one or more of VYNE’s patent applications may not be granted and potential competitors may also seek to design around VYNE’s granted patents or patent applications; additional competition in the acne and dermatology markets; risks related to our indebtedness; inability to raise additional capital on favorable terms or at all; VYNE’s ability to recruit and retain key employees; and VYNE’s ability to stay in compliance with applicable laws, rules and regulations. If a woman becomes pregnant while using AMZEEQ, she should talk to her doctor. It is not known if AMZEEQ is safe and effective in children under 9 years of age. VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update. However, some individuals, particularly women, can experience acne much later in life. Tetracycline medicine when taken by mouth during pregnancy, infancy and/or childhood up to the age of 8 years may permanently discolor teeth (yellow-gray-brown) and may slow the growth of bones. Specifically, the FDA-approved AMZEEQ label now provides that with respect to resistance, P. acnes strains displayed a low propensity for the development of resistance to minocycline, with spontaneous mutation frequencies occurring <10−8 (or 1 in 100 million) at 2 to 16 times the minimum inhibitory concentration (MIC). VYNE Therapeutics surged ~39% since FDA approval for label update Benzinga 12d Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More About VYNE Therapeutics Inc. VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. The FDA approval of ZILXI is primarily supported by data from two clinical trials in 1,522 patients 18 years of age and older. The studies concluded that on-target potency remained consistently high (MIC90 = 0.25µg/ml) when tested in clinical isolates of P. acnes. For more information about VYNE Therapeutics Inc. or its investigational products, visit www. About VYNE Therapeutics Inc. ... 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. Both products are available nationwide. These are not all of the possible side effects with AMZEEQ. For most people, acne diminishes over time and tends to disappear or decrease, by age 25. BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval by the U.S. Food and Drug Administration (“FDA”) to include new … Use of AMZEEQ should be stopped right away if a rash or other allergic symptom occurs. BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval by the U.S. Food and Drug Administration (“FDA”) to include new information in the product label for AMZEEQ® (minocycline) topical foam, 4% referencing the low propensity of P. acnes strains to develop resistance to minocycline, the active ingredient in AMZEEQ. When taken by mouth, minocycline may cause feelings of lightheadedness, dizziness or spinning. AMZEEQ should not be used in women who are pregnant, may become pregnant or are nursing. AMZEEQ was FDA approved in October 2019 and ZILXI was approved by the FDA in May 2020. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. It is not known if AMZEEQ is safe and effective in children under 9 years of age. Company on track to initiate the TRILOGY Phase 3 program in 2021BRIDGEWATER, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) , … Further, the prevalence of minocycline-resistant strains as assessed by spontaneous mutation frequency was low (range: <2.7×10-9 to <1.30×10-8 colony forming units) when exposed to minocycline at concentrations up to 16-fold higher than the mean minimum inhibitory concentration (MIC). People should not drive or operate dangerous machinery if they have these symptoms. All statements in this press release which are not historical facts are forward-looking statements. The use of antibiotics to counteract the effect of this bacterium remains a major cornerstone of acne disease management, although concerns over the development of antibiotic-resistant strains are factors in a prescriber’s choice of antibiotic and route of administration. AMZEEQ® label update includes new information indicating the low propensity of Propionibacterium acnes (more commonly known as “P. “We are pleased that the inclusion of this valuable additional information for AMZEEQ will support prescribers in making informed decisions on both their choice of antibiotic and administration route when selecting a treatment for acne.”. BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of … VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update. Development milestones include: Top-line results released for first two phase 3 pivotal studies AMZEEQ is available by prescription only. VYNE Therapeutics Announces Reverse Stock Split . BRIDGEWATER, N.J., Feb. 01, 2021 — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval by the U.S. Food and Drug Administration (“FDA”) to include new information in the product label for … Tetracycline medicine when taken by mouth during pregnancy, infancy and/or childhood up to the age of 8 years may permanently discolor teeth (yellow-gray-brown) and may slow the growth of bones. AMZEEQ® label update includes new information indicating the low propensity of Propionibacterium acnes (more commonly known as “P. It is characterized by both inflammatory lesions (papules and pustules) and non-inflammatory lesions (open and closed comedones) affecting primarily the face and truncal areas of the body. AMZEEQ is for use on skin only (topical use). These are not all of the possible side effects with AMZEEQ. For more information about VYNE Therapeutics Inc. or its investigational products, visit www. Use of AMZEEQ should be stopped right away if a rash or other allergic symptom occurs. VYNE Therapeutics Announces FDA Approval Of AMZEEQ Label Update. BRIDGEWATER, N.J., Feb 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- BRIDGEWATER, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE… When taken by mouth, minocycline may cause feelings of lightheadedness, dizziness or spinning. AMZEEQ is a topical foam that contains minocycline, a tetracycline medicine. Recently in News on February 1, 2021, VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update. WELCOME TO THE STOCKGURU TEAM!!! Visit www.fda.gov/medwatch or call 1-800-FDA-1088. People should protect their skin from the sun while using AMZEEQ and avoid sunlight or artificial sunlight such as sunlamps or tanning beds. People should contact their doctor for medical advice about side effects and be sure to tell their doctor about all of their medical conditions and medicines they take before using AMZEEQ. The most common side effect of AMZEEQ is headache. We are here to help you succeed in everything you do and although this is a journey you are taking the first step towards success and we at StockGuru thank you for your continued support. AMZEEQ should not be used in people who are allergic to AMZEEQ or any tetracycline medicine. People should contact their doctor for medical advice about side effects and be sure to tell their doctor about all of their medical conditions and medicines they take before using AMZEEQ. acnes”) to develop resistance to minocyclineBRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on … NASDAQ 0.40%. AMZEEQ is for use on skin only (topical use). acnes”) to develop resistance to minocycline. Amongst other objectives, the antimicrobial characterization program conducted by VYNE to support this label update evaluated on-target potency of AMZEEQ and minocycline against P. acnes and further evaluated the potential for the development of minocycline-resistant strains that could reduce the potency of AMZEEQ in the treatment of acne. AMZEEQ is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. For most people, acne diminishes over time and tends to disappear or decrease, by age 25. VYNE Therapeutics surged ~39% since FDA approval for label update Benzinga 12d Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More Antimicrobial Susceptibility and Genetic Characteristics of Propionibacterium Acnes Isolated from Patients with Acne. The FDA approval was supported by an extensive antimicrobial characterization program by VYNE for both AMZEEQ and minocycline that was published last … For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in VYNE’s subsequent filings with the U.S. Securities and Exchange Commission. BRIDGEWATER, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced listing another U.S. patent in the FDA’s Approved Drug Products with … BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced approval by the U.S. Food and Drug Administration (“FDA”) to include new … “The risk of antimicrobial resistance is a primary concern for dermatologists or, indeed, any routine prescriber of antibiotics,” said David Domzalski, CEO of VYNE.
What To Do In Seville In February,
Whole30 Salmon Burgers,
Clean Logic Foam Sea Sponge,
Prokat 2200 Cc Specs,
Counterculture Movement Events,
Touch Up Spray Gun Home Depot,